Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Hoffarth

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Oncogene|October 10, 2003
The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspasesJavorina Milosevic, Sandra Hoffarth, Claudia Huber, et al.
Journal of Cancer Research and Clinical Oncology|April 11, 2012
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancerJohannes Meiler, Melanie Guyot, Sandra Hoffarth, et al.
International Journal of Cancer|August 11, 2007
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancerEmmanuelle Wesarg, Sandra Hoffarth, Rainer Wiewrodt, et al.
Blood|August 12, 2008
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosisClaudia Stolz, Georg Hess, Patricia S Hähnel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancerSilvan Becker, Boyka Markova, Rainer Wiewrodt, et al.
Plos One|January 28, 2014
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patientsFrank Breitenbuecher, Sandra Hoffarth, Karl Worm, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Oncogene|October 10, 2003
The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspasesJavorina Milosevic, Sandra Hoffarth, Claudia Huber, et al.
Journal of Cancer Research and Clinical Oncology|April 11, 2012
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancerJohannes Meiler, Melanie Guyot, Sandra Hoffarth, et al.
International Journal of Cancer|August 11, 2007
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancerEmmanuelle Wesarg, Sandra Hoffarth, Rainer Wiewrodt, et al.
Blood|August 12, 2008
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosisClaudia Stolz, Georg Hess, Patricia S Hähnel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancerSilvan Becker, Boyka Markova, Rainer Wiewrodt, et al.
Plos One|January 28, 2014
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patientsFrank Breitenbuecher, Sandra Hoffarth, Karl Worm, et al.
Pageof 1